Among the eight nonresponder patients with cervical cancer, four received everolimus on the basis of PIK3CA mutation (Glu545Lys), two on the basis of PTEN inactivation, and two on the basis of AKT1 mutation (Glu17Lys). This evidence concerns the gene PIK3CA and cervical cancer.